Evaluation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients on dialysis with either 2.5 or 3.0 mEq/L of dialysate calcium concentration

Evaluation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients on dialysis with either 2.5 or 3.0 mEq/L of dialysate calcium concentration - Evaluation of efficacy and safety of lanthanum carbonate in hyperphosphatemia patients with either 2.5 or 3.0 mEq/L of dialysate calcium concentration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002820

Enrollment

200

Registered

2009-12-01

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis patients with hyperphosphatemia

Interventions

Lanthanum carbonate treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hemodialysis pts 2) Hyperphosphatemia pts treated with phosphate binder or hyperphosphatemia pts needed to start phosphate binder treatment

Exclusion criteria

Exclusion criteria: 1) Pts who meet the contraindiation criteria in package insert of lanthanum carbonate 2) Pregnant or possibly pregnant pts, pts on lactation 3) Inappropriate pts for this study according to the investigator's judgment

Design outcomes

Primary

Measure	Time frame
Serum phosphate, serum calcium and serum Ca x P product level and intact-PTH	—

Secondary

Measure	Time frame
Adverse events, drug compliance	—

Countries

Japan

Contacts

Public ContactHiroshi Yamamoto

Rakuwakai Otowa Kinen Hospital Department of Neprology

075-594-8010

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026